… Drug development, from testing through approval, can take decades and billions … ready for full review, the FDA requests more information from the drugmaker.  During review, the FDA evaluates drug safety and efficacy data (from the clinical trials) and information for the drug’s …

… was handed a  REM sleep behavior disorder (RBD) diagnosis from a sleep doctor in 2022. RBD is a condition in which … So, I started looking for information.”  Cindy, 65, from Santa Rosa, California, found The Michael J. Fox … lies the hope,” she said.  Cindy is aware that findings from PPMI (such as the new biomarker test announced last …

… This week, results from a clinical study published in the New England Journal … company that is a provider of DBS, these results were taken from the first large, multicenter, randomized, controlled … mean treating younger patients. Also, we’re still far from understanding if DBS has any disease-modifying effects; …

… attention to include: An inhaled formulation of levodopa from Civitas Therapeutics which is currently in the second … of clinical testing. A levodopa/carbidopa “pump patch” from Israeli drugmaker Neuroderm that the Foundation will … An improved pill formulation called an “accordion pill” from Intec Pharmaceuticals.  In addition, in 2012 AbbVie …

… Chris Woods during the 2010 ride One month from today, hundreds of cyclists will come together in Old … been able to meet a fabulous and inspiring group of people. From training and finishing with my husband, sons and family … The ride has grown substantially over the last six years from just 35 riders raising $27,000 in 2008 to over 440 in …

… the search for these elusive endpoints as being far removed from us when in fact, we need to be an integral part of the … for a new treatment for a neurologic disease to get from the lab counter to the pharmacy shelf, it can take anywhere from 15 to 30 years and about $1 billion of investment. …